FCMT
KIN

Founders Capital Management (Texas)’s Kindred Biosciences, Inc. KIN Stock Holding History

Founders Capital Management (Texas)’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,500
Closed -$14K – 336
2021
Q2 		$14K Hold
1,500
– – 0.01% 240
2021
Q1 		$7K Hold
1,500
– – 0.01% 265
2020
Q4 		$6K Buy
+1,500
New +$6.1K ﹤0.01% 270
2020
Q1 		$6K Hold
1,500
– – 0.01% 265
2019
Q4 		$13K Hold
1,500
– – 0.01% 231
2019
Q3 		$10K Hold
1,500
– – 0.01% 254
2019
Q2 		$12K Hold
1,500
– – 0.01% 246
2019
Q1 		$14K Hold
1,500
– – 0.01% 226
2018
Q4 		$16K Hold
1,500
– – 0.02% 198
2018
Q3 		$21K Sell
1,500
-500
-25% -$6.76K 0.02% 179
2018
Q2 		$21K Hold
2,000
– – 0.02% 181
2018
Q1 		$17K Hold
2,000
– – 0.01% 229
2017
Q4 		$19K Hold
2,000
– – 0.02% 219
2017
Q3 		$16K Hold
2,000
– – 0.01% 231
2017
Q2 		$17K Hold
2,000
– – 0.02% 225
2017
Q1 		$14K Buy
+2,000
New +$12.5K 0.01% 253

Other funds holding KIN

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Founders Capital Management (Texas)'s KIN Position: Q3 2021 in Review

Founders Capital Management (Texas) sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 1,500 shares — an estimated $14K sold.

Founders Capital Management (Texas) first reported a position in KIN in Q1 2017 and held it in 16 quarters. The position peaked at $21K in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

  • Founders Capital Management (Texas) reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 1,500 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $14K.
  • Founders Capital Management (Texas) first reported a position in Kindred Biosciences, Inc. in Q1 2017 and held it in 16 quarters.
  • Founders Capital Management (Texas)'s Kindred Biosciences, Inc. position peaked at $21K in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2021, filed 12 Oct 2021.